WorldCat Identities

Fox Chase Cancer Center

Overview
Works: 154 works in 312 publications in 1 language and 654 library holdings
Genres: Periodicals  Handbooks and manuals  Directories 
Classifications: RC267, 616
Publication Timeline
.
Most widely held works about Fox Chase Cancer Center
 
moreShow More Titles
fewerShow Fewer Titles
Most widely held works by Fox Chase Cancer Center
Scientific report by Pa.) Institute for Cancer Research (Philadelphia( )

in English and held by 213 WorldCat member libraries worldwide

Fox Chase Cancer Center : Scientific Report 2003, basic science, medical science, population science by Fox Chase Cancer Center( Book )

18 editions published between 1995 and 2006 in English and held by 61 WorldCat member libraries worldwide

Tobacco-free youth : developing coalitions for tobacco-free youth( Book )

1 edition published in 1996 in English and held by 18 WorldCat member libraries worldwide

Pennsylvania tobacco control resource directory( Book )

2 editions published in 1996 in English and held by 15 WorldCat member libraries worldwide

Talking about your cancer : a parent's guide to helping children cope( Visual )

1 edition published in 1996 in English and held by 14 WorldCat member libraries worldwide

Designed to help parents with a new diagnosis of cancer explain the illness to their children. Deals with finding the words, when and how to tell children, dealing with fears, explaining side effects, the importance of hope and working together, support services, problematic childhood behaviors, and how the school can help
The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel by Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel <1997>( Book )

9 editions published between 1997 and 1999 in English and held by 14 WorldCat member libraries worldwide

Institute for cancer research : twenty-ninth scientific report ; and, American Oncologic Hospital : first scientific report by Fox Chase Cancer Center( Book )

5 editions published between 1984 and 1986 in English and held by 10 WorldCat member libraries worldwide

The Fox Chase Cancer Center Investigators' Workshop and Consensus Conference : March 4-6, 1999, Lana'i, Hawaii by Fox Chase Cancer Center( Book )

1 edition published in 1999 in English and held by 8 WorldCat member libraries worldwide

Chemotherapy with platinum compounds : current status and future directions : February 24-28, 1993, Kona, Hawaii : proceedings of the Fox Chase Cancer Center Workshop on the Role of Platinum Compounds in Cancer Treatment by Fox Chase Cancer Center Workshop on the Role of Platinum Compounds in Cancer Treatment( Book )

1 edition published in 1994 in English and held by 4 WorldCat member libraries worldwide

Scientific report by Pa.) Institute for Cancer Research (Philadelphia( Book )

2 editions published in 1986 in English and held by 4 WorldCat member libraries worldwide

Identification of Two Candidate Tumor Suppressor Genes on Chromosome 17p13.3: Assessment of Their Roles in Breast and Ovarian Carcinogenesis( Book )

5 editions published between 1997 and 2001 in English and held by 3 WorldCat member libraries worldwide

We have identified a region of less than 30 kbp, on chromosome 17p13.3 by allelic loss mapping, which is altered in>50% of the breast tumors analyzed. Using positional cloning techniques we have identified several genes, one which we refer to as OVCA2, that fall within this critical region. To date, we have found that: (1) OVCA2 is a new gene residing in a chromosomal region which is frequently lost in breast, brain, colon, ovarian tumors, acute myeloid leukemia and myelodysplastic syndromes, (2) OVCA2 is a secretory protein which is highly evolutionarily conserved, (3) OVCA2 (25 kDa) is proteolytically processed to its mature form (21 kDa), (4) p21 is present in normal blood serum and in breast nipple aspirate fluid, (5) both forms of OVCA2 are present in a variety of tissues, including mammary epithelium, (6) secretion of OVCA2 into the breast lumen is dependent on the developmental stage of the mammary gland, and (7) secreted OVCA2 appears to be lower in most breast tumors, relative to normal mammary epithelial cells. The recent detection of p21OVCA2 in normal serum and NAF, suggests that OVCA2 could be a new hormone with an important paracrine function. Identifying the potential role of OVCA2 in the development and the pathogenesis of the breast might ultimately help us to better understand the disease and to plan more effective treatment strategies
Establishment of the Fox Chase Network Breast Cancer Risk Registry( Book )

6 editions published between 1995 and 1998 in English and held by 2 WorldCat member libraries worldwide

The wealth of research regarding the complex interaction of the genetic, biologic and environmental factors associated with breast carcinogenesis offers promise towards better understanding of breast cancer. The progress in molecular genetics provides us with opportunities to expand our knowledge about modifiable causes of breast cancer. The development of the Fox Chase Cancer Center Breast Cancer Risk Registry was proposed to facilitate research in the epidemiologic and genetic predictors of disease and permitted evaluation of the effectiveness of new risk counseling, surveillance and prevention strategies. Staff training, sharing resources and administrative support were critical components to assist the community hospital to develop a high-risk program. Formal and on-going inservice training in cancer genetics, breast cancer risk and genetic educational resources, telephone consultation, DNA blood collection procedures, and continuous monitoring were necessary for implementation and coordination of a community-based risk registry. The establishment of an Advisory Panel helped address additional issues of informed consent, reimbursement, and community-based counseling strategies. This project demonstrates that with appropriate resources and support, it is feasible to establish a registry for individuals at high risk for breast cancer and further our understanding of the genetic and epidemiologic basis of the disease
Genetic Determinants of Breast Cancer Metastasis( Book )

4 editions published between 1998 and 2000 in English and held by 1 WorldCat member library worldwide

The existence of metastatic suppressor genes was originally predicted based on somatic cell hybrid fusions between nonmetastatic and metastatic tumor cells. The resulting hybrids, whil% retaining their tumorigenic potential, were unable to metastasize 1-3. A prostate cancer metastatic suppressor locus was localized on human chromosome 11 in the region lip1 1.2 and was subsequently shown to be KM 1, a leukocyte surface glycoprotein 4. Analysis of murine melanoma and human breast cancer cell lines revealed the specific down regulation of the gene NM23, a nucleoside 5'-phosphate kinase in metastatic tumors or cell lines versus nonmetastatic samples 5. Introduction of E-cadherin cDNAs into tumor cell lines has demonstrated the suppression of metastatic capacity of both mouse and human carcinomas 6-8. Additional evidence for the existence of genes that can suppress metastasis was generated from a series of transfection experiments into murine cells. It was determined that a variety of activated proto-oncogenes, including H-RAS, v-mos, v-raf, A-RAF, v-src, v-fes, v-fms, and p53 could induce primary tumors with metastatic dissemination when transfected NIH-3T3 cells were injected into mice. However, when the same oncogenes were transfected into cell lines derived from different strains of mice, metastatic potential, but not tumorigenicity, was lost 9, 10. This suggests that certain alleles present in some of the inbred strains of mice, either alone or in combination, can function as a metastasis suppressor. At present, these loci have yet to be characterized
Quality of Life After Prophylactic Oophorectomy( )

5 editions published between 2001 and 2005 in English and held by 0 WorldCat member libraries worldwide

Risk reducing surgery remains an important option for women at risk for ovarian cancer, yet the quality of life implications of such surgery are vastly understudied. Our effort to prospectively study women who choose prophylactic surgery is providing much-needed feedback for other women who seek counseling regarding cancer risk reduction strategies. Further, comparing women undergoing surgery with a control group of those who opt not to pursue it provides a more rigorous scientific perspective to support clinical management. Pertinent findings from interim analysis presented here show statistically significant short term differences between groups with the surgery group experiencing more hot flashes, night sweats, decrease in physical and social functioning and decrease in sexual activity frequency and pleasure. There is no difference in self-concept between groups. The coming year will allow for completion of data collection and final comprehensive analysis to determine changes in quality of life over time and between the two groups. This study's outcomes will be directly translatable to the women who need this important information to develop coping strategies for increased risk of ovarian cancer
Evaluation of Feasibility for a Case-Control Study of Pituitary-0varian Function in Premenopausal Women With Breast Cancer( )

5 editions published between 2003 and 2006 in English and held by 0 WorldCat member libraries worldwide

Postmenopausal women with elevated serum estrogens and androgens are at an increased risk of breast cancer. Dehydroepiandrosterone sulfate (DHEAS) is secreted only by the adrenals, and elevated serum DHEAS levels in postmenopausal women who develop breast cancer suggest increased adrenal androgen production. The objective of the pilot study is to evaluate the feasibility of conducting a case-control study that uses adrenocorticotropic hormone (ACTH) stimulation tests to determine if postmenopausal women who develop breast cancer secrete more adrenal androgens, which are converted to estrogens in peripheral tissues, in response to ACTH stimulation compared to unaffected women. Hypotheses to be tested in the full-scale study are: 1) greater adrenal responsiveness to ACTH contributes to elevated serum concentrations of androgens and estrogens in postmenopausal women who develop breast cancer; and 2) increased adrenal androgen production in postmenopausal women with breast cancer is related to increased enzyme activity at a specific step in steroidogenesis rather than to generalized enhancement of adrenal androgen production. Cellular immune function also has been hypothesized to play a role in breast cancer etiology, and cortisol, which is another hormone that is secreted by the adrenals, is immunosuppressive (i.e., causes significant decreases in numbers and percentages of lymphocytes in the blood). At no additional cost to DOD we are also collecting preliminary data to begin to address the hypothesis that greater adrenal responsiveness to ACTH contributes to greater immunosuppression in postmenopausal women who develop breast cancer
The Nuclear Death Domain Protein p84N5; a Candidate Breast Cancer Susceptibility Gene( )

4 editions published between 2004 and 2007 in English and held by 0 WorldCat member libraries worldwide

Besides family history of cancer and an individual's age, no single etiologic factor can identify women at an increased risk for the disease. Approximately 10% of all cases of breast cancer exhibit a familial pattern of incidence. Efforts to identify the genetic basis of familial breast cancer reached fruition some years ago, when the breast cancer susceptibility genes, BRCA1 and BRCA2 were identified. However, recent studies have suggested that mutations in these genes are associated with a smaller number (20% to 60%) of hereditary breast cancer families than originally estimated, especially in studies that have been based on population-based family materials. Several research groups, including the author's, are searching for additional breast cancer susceptibility genes using whole genome scanning approaches, but the success of many of these approaches depends on the underlying heterogeneity of the remaining cancer susceptibility loci. The failure to identify additional breast cancer susceptibility genes associated with a high risk of disease suggests that more than one may exist. The author has taken the approach that the next BRCA genes will be those that encode for proteins whose functions are linked to important cell regulatory pathways. His group has recently found one such candidate BRCA3 protein, referred to as p84N5
Targeting Breast Cancer with Anti HER2/neu Diabodies( )

5 editions published between 1999 and 2003 in English and held by 0 WorldCat member libraries worldwide

The objective of this proposal is to develop new therapeutic reagents for breast cancer. It is our hypothesis that improved diabody-based molecules with affinity for HER2/neu can be engineered and will prove to be effective vehicles for the radioimmunotherapy (RAIT) of breast cancer. The first Technical Objective (T.O.) focuses on the optimization of the production of the selected diabody and the identification of the optimal radionuclide and labeling strategy for diabody-based RAIT. This T.O. also involves an investigation into the impact on diabody targeting and RAIT of a variety of factors likely to be encountered in a clinical setting. These include the degree of antigen density, the route (i.v. bolus or continuous infusion) and frequency of administration, the presence of disseminated disease, and the effect of antigen expression on normal tissues. Completion of these experiments will set the stage for proceeding to the clinical evaluation of diabody-based targeting of breast cancer in our second Technical Objective. The clinical component of this proposal (to be initiated in year 3) will entail a Phase I radioimmunoimaging and radioimmunoguided surgery trial designed to elicit information on the dosimetry, specificity and tumor penetration properties of radiolabeled C6.5 diabody, and will assess the RAIT potential of this molecule
Reversal of Multidrug Resistance in Breast Cancer( )

4 editions published between 1994 and 1997 in English and held by 0 WorldCat member libraries worldwide

Our data show that MDR'1 gene expression is important in breast cancer resistance. The role of the MDRl gene in breast cancer treatment will be further defined by sequentially determining MDRl gene expression pre and post treatment with doxorubicin in the context of three prospective clinical trials. In addition, this study will allow a correlation of MDRl gene expression and clinical outcome. To determine what level of MDRl gene expression is clinically significant, various molecular methods of determining MDR 1 gene expression, including immunohistochemistry and quantitative reverse transcription followed by polymerase chain reaction, will be evaluated. MDR can be reversed in vitro and we will test this hypothesis in a Phase I study of cyclosporin A and quinine as MDR reversers of vinblastine resistance. Together these studies will address the major goal of circumventing drug resistance in breast cancer. When the data of the MDRl gene expression in breast cancer specimens from this proposal are available, clinical trials incorporating the modulators of MDR, cyclosporin and quinine, will be designed for breast cancer as well. An alteration in drug efflux potentially may have an impact on response to chemotherapy and may result in improved survival for breast cancer patients. During the period between March 15, 1993 and March 14, 1995, we have outfitted our laboratory with staff, equipment, supplies and reagents and have been performing control experiments and have been pursuing activation of the various clinical trials to support this project
Tailored Communication to Enhance Adaptation Across the Breast Cancer Spectrum( )

6 editions published between 2002 and 2007 in English and held by 0 WorldCat member libraries worldwide

Breast cancer represents a serious health concern for women, across the disease spectrum. First despite advances in technology used for intensive disease surveillance and innovative preventive options, interest in and utilization of these technologies is less than optimal, especially among low-income, African-American women and first-degree relatives. Second, among women who have completed cancer treatment, psychological after-effects that can have a negative impact on adjustment and adherence to screening practices are prevalent. Finally, for those cancer patients whose disease has metastasized, clinically relevant psychosocial adjustment problems need to be recognized and managed. It is for these reasons that research leading to improvements in quality of life throughout the disease spectrum is necessary. The Behavioral Center for Excellence, through the coordination of four projects, seeks to understand and evaluate psychosocial approaches for promoting psychological and physical adaptation to cancer risk, treatment and survival. Each project systematically assesses and addresses barriers to, and facilitators of, adjustment and adherence and evaluates interventions designed for this cause. With support from four core facilities, the BCE has assembled a multi-disciplinary research team to conduct an interrelated set of studies that are theoretically-guided, thematically convergent, and synergistic in the impact on the behavioral aspects of breast cancer
Facilitating Treatment Decision Making, Adjustment and Coping in Men Newly Diagnosed With Prostate Cancer( )

4 editions published between 2001 and 2004 in English and held by 0 WorldCat member libraries worldwide

The study evaluates an intervention designed to facilitate treatment decision making, adjustment, and coping among early-stage prostate cancer patients and their spouse/partners, in a randomized controlled trial. The intervention is based on the Cognitive-Social Health Information Processing (C-SHIP) framework that postulates that decision making is determined by cognitive factors (i.e., perceptions about vulnerability; expectancies and beliefs; values and goals), affective factors (i.e., concerns and worry about the disease and its treatment), as well as self-regulatory skills (i.e., the ability to manage distress and effectively execute recommended behaviors) . To date, we have 300 couples enrolled in the study; 6 month follow-up questionnaires have been sent to 232 couples with 205 patients (88%) and 160 (69%) spouses/partners completed; 12-month follow-up questionnaires have been sent to 182 patients and 160 spouse/partners who remain in the study. We now have a total of 166 patients (91% return) and 150 spouse/partners (94% return) who have completed all of the required assessment for the study. Preliminary data analyses point to the acceptability and efficacy of the Cognitive and Affective Reactions and Expectations (CARE) intervention compared to General Health Intervention (GHI), not only in the short-term but also in the long-term at 6-months post baseline
 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.57 (from 0.14 for Fox Chase ... to 0.97 for The Nuclea ...)

Alternative Names

controlled identityFox Chase Center for Cancer and Medical Sciences

FCCC

Fox Chase Cancer Center

Fox Chase Center for Cancer and Medical Sciences

フォックス・チェイス・癌センター

福克斯·蔡斯癌症中心

Languages
English (105)